Immunome, Inc. (IMNM) is a publicly traded Healthcare sector company. As of May 20, 2026, IMNM trades at $21.47 with a market cap of $2.25B and a P/E ratio of -8.89. IMNM moved +9.59% today. Year to date, IMNM is +9.23%; over the trailing twelve months it is +151.52%. Its 52-week range spans $5.15 to $27.65. Analyst consensus is strong buy with an average price target of $35.17. Rallies surfaces IMNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own IMNM include Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immunome, Inc..
| Metric | Value |
|---|---|
| Price | $21.47 |
| Market Cap | $2.25B |
| P/E Ratio | -8.89 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.65 |
| 52-Week Low | $5.15 |
| Volume | 1.14M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.01M |
| Net Income | $-224.59M |
| Gross Margin | 0.00% |
14 analysts cover IMNM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.17.